Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients.

about

Early viral kinetics: a novel guide for optimal dosing frequency of pegylated interferon-α-2a in HIV/HCV-coinfected patients.

Item

http://www.wikidata.org/entity/Q50554938

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@en

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@nl

type

Item

label

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@en

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@nl

prefLabel

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@en

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@nl

P1476

Early viral kinetics: a novel ...... n HIV/HCV-coinfected patients.

@en

P2093

Laura Milazzo

http://www.w3.org/2001/XMLSchema#string

Miriam Cesari

http://www.w3.org/2001/XMLSchema#string

P2860

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

Telaprevir for previously untreated chronic hepatitis C virus infection

Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy

Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics.

EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

Pharmacodynamics of PEG-IFN-alpha-2a in HIV/HCV co-infected patients: implications for treatment outcomes

HCV RNA decline in the first 24 h exhibits high negative predictive value of sustained virologic response in HIV/HCV genotype 1 co-infected patients treated with peginterferon and ribavirin

Hepatitis C Viral Kinetics in Special Populations

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial.

Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.

P304

859-862

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERI.11.100

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21973297

http://www.w3.org/2001/XMLSchema#string